Patent · US Active

7,8-dihydropyrido[2,3-d]pyrimidin-4-yl substituted compounds as inhibitors of p38 kinase

US8354416B2 · kind B2 · utility

0Cited by

96References

30Claims

0Family size

Assignee

Glaxo Group Limited · GB

Inventors

James Francis Callahan · Philadelphia, US
Jeffrey C. Boehm · King of Prussia, US
Anthony William James Cooper · Stevenage, GB
Stefano Livia · Stevenage, GB
Paul Bamborough · Stevenage, GB
Neysa Nevins · Collegeville, US
Zehong Wan · King of Prussia, US
Beth Adams Norton · Durham, US
Xichen Lin · Shanghai, CN

Key dates

Filing date	Jun 4, 2008
Grant date	Jan 15, 2013
Priority date	—
Expiry date	Aug 15, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.